Archives press 2013

CTAD Press releases 2013

Daily release Thursday, November 14th Press Release

CTAD 2013 Media Summary November 14th Media Summary

• FDA’S Rusty Katz receives the CTAD Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research Press Release.
• Novel Cognitive Outcomes for Preclinical Alzheimer’s Disease Prevention Trials. 
• Tau in the brain: a better predictor of Alzheimer's disease progression ?
• Symposium 2 Rethinking the way to conduct drug trials in Alzheimer's Disease.

Daily release Friday, November 15^th 

• Symposium 3 : Agitation and Depression in AD.
• Down syndrome and AD : Dr. William Mobley. 

Daily release Saturday, November 16^th 

• Additional article for Dr. Holtzman.

Articles on CTAD

• Are New Cognitive Tests Ready For Preclinical Trials?
• Alzheimer’s Forum: Growth Factor Therapy:  Safe in Phase 1, Awaiting Efficacy
• Clinical Neurology News Cholinesterase inhibitors most effective in Mild AD
• Clinical Psychiatry News  Memantine helped to delay driving impairment in early Alzheimer’s
• Hispanic Business News Boston Scientific Meets Co-primary 
• Medscape Neurology Medical news from the 6th CTAD
• San Diego Union Tribune CTAD and Preclinical Trials
• Surgery News – American College of Surgeons Nerve Growth Factor Delivered Safely in Alzheimer’s
• 4Traders Eye Test Results Impressive
• Clinical Neurology News  NGF Delivered
• Alzheimer’s Forum Do Tau Tracers Track Cognitive Decline
• Biotuesdays Agitation and Depression in AD - Transition Therapeutics CTAD Presentations
• The Motley Fool “3 Drugmakers on the Move”
• Clinical Psychiatry News Digital Network: Subjective Memory Complaints Predict Clinical Impairment

Keynote Slides

The following keynote presentations are available for download :

• Toward effective Alzheimer’s therapy: progress and collaboration
  Paul Aisen, MD, University of California at San Diego, USA
• Designing drug trials taking into account neuropsychiatric symptoms of AD
  Jeffrey Cummings, MD, Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV – USA
• Ethical issues in AD prevention trials: genetics, biomarkers and treatment risk
  Serge Gauthier, MD, FRCPC, McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal, Canada
• Novel immunotherapy approaches 
  David Holtzman, MD, Professor and Chairman of Neurology, Associate Director of the Alzheimer’s Disease Research Center, Washington University in St. Louis, MO – USA